[1]高之晔,韩星敏.放射性核素标记的胆碱在PET/CT肿瘤显像中的应用[J].国际放射医学核医学杂志,2018,(3):280-285.[doi:10.3760/cma.j.issn.1673-4114.2018.03.016]
　Gao Zhiye,Han Xingmin.Application of radionuclide-labeled choline in PET/CT tumor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(3):280-285.[doi:10.3760/cma.j.issn.1673-4114.2018.03.016]
点击复制

放射性核素标记的胆碱在PET/CT肿瘤显像中的应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第3期
页码:
280-285
栏目:
综述
出版日期:
2018-05-25

文章信息/Info

Title:
Application of radionuclide-labeled choline in PET/CT tumor imaging
作者:
高之晔;  韩星敏
450052, 郑州大学第一附属医院核医学科, 河南省分子影像医学重点实验室
Author(s):
Gao Zhiye;  Han Xingmin
Department of Nuclear Medicine, First Affiliated Hospital of Zhengzhou University, Henan Medical Key Laboratory of Molecular Imaging, Zhengzhou 450052, China
关键词:
胆碱; 放射性同位素; 正电子发射断层显像计算机体层摄影术; 肿瘤
Keywords:
Choline; Radioisotopes; Positron emission tomography computed tomography; Neoplasms
DOI:
10.3760/cma.j.issn.1673-4114.2018.03.016
摘要:
18F-FDG PET/CT可明显提高恶性肿瘤诊断的准确性，指导恶性肿瘤的分期与再分期，对患者治疗方案的选择产生了重要影响。其在全身许多肿瘤中的应用价值已获得认可，但还存在一些不足。随着正电子标记药物的不断研发，放射性核素标记的胆碱逐渐应用于临床。胆碱是细胞膜的重要组成成分，恶性肿瘤的胆碱代谢增高。近年来的研究表明，胆碱PET/CT在胶质瘤、头颈部肿瘤、肺癌、肝细胞肝癌、前列腺癌、膀胱肿瘤等的诊断、分期及复发检测等方面具有很好的应用价值，特别是对颅内病变的观察、高分化肝细胞肝癌的诊断、生物靶区勾画、复发病灶的定位等，在一定程度上弥补了18F-FDG PET/CT的不足。笔者回顾了放射性核素标记的胆碱（11C-胆碱和18F-胆碱）在肿瘤显像中的应用。
Abstract:
18F-FDG PET/CT has significantly enhanced the accuracy of diagnosing malignant tumors, guided the staging and restaging of malignant tumors, and considerably impacted the treatment of patients. The importance of the clinical application of this technology in many tumors has been recognized, but several deficiencies remain. With the development of positron imaging agent, radionuclide-labeled choline has been increasingly applied in clinical research. Choline is an important component of the cell membrane, and its metabolism increases malignant tumors. Recent studies have shown that choline PET/CT has good value in the diagnosis, staging, and recurrence detection of glioma, head and neck cancer, lung cancer, hepatocellular carcinoma, prostate cancer, and bladder cancer. This technology is especially beneficial for observing intracranial lesions, diagnosing well-differentiated hepatocellular carcinoma, and mapping the biological target area and location of recurrent lesions. Therefore, choline PET/CT complements the deficiency of FDG PET/CT to some extent. This paper reviews the application of radionuclide-labeled choline (11C-choline/18F-choline) in tumor imaging.

参考文献/References:

[1] 李亚军, 张慧娟. 放射性核素标记胆碱与18F-FDG PET肿瘤显像的对比研究[J]. 国际放射医学核医学杂志, 2010, 34(6):348-352. DOI:10.3760/cma.j.issn.1673-4114. 2010.06.007. Li YJ, Zhang HJ. Comparison choline with 18F-FDG PET in various tumors imaging[J]. Inter J Radiat Med Nucl Med, 2010, 34(6):348-352.
[2] Salem N, Kuang Y, Wang F, et al. PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose,[1-11C]-acetate and[N-methyl-11C]-choline[J]. Q J Nucl Med Mol Imaging, 2009, 53(2):144-156.
[3] Tolvanen T, Yli-Kerttula T, Ujula T, et al. Biodistribution and radiation dosimetry of[11C]choline:a comparison between rat and human data[J]. Eur J Nucl Med Mol Imaging, 2010, 37(5):874-883. DOI:10.1007/s00259-009-1346-z.
[4] 吴战宏, 王世真, 周前, 等. 18F标记氟乙基胆碱的合成与动物显像[J]. 中华核医学杂志, 2005, 25(3):138-140. DOI:10.3760/cma.j.issn.2095-2848.2005.03.004. Wu ZH, Wang SZ, Zhou Q, et al. Synthesis and animal imaging of 18F-FECh[J]. Chin J Nucl Med, 2005, 25(3):138-140.
[5] 李彦鹏, 温馨, 程兵, 等. (N-[18F]氟甲基)-胆碱的自动化合成及其生物分布研究[J]. 同位素, 2017, 30(1):29-35. DOI:10.7538/tws.2017.30.01.0029. Li YP, Wen X, Cheng B, et al. Automated Radiosynthesis and Bio-distribution of[18F]Fluoromethyl Choline[J]. J Isotopes, 2017, 30(1):29-35.
[6] Treglia G, Giovannini E, Di Franco D, et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer:a systematic review[J]. Ann Nucl Med, 2012, 26(6):451-461. DOI:10.1007/s12149-012-0602-7.
[7] Kato T, Shinoda J, Nakayama N, et al. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography[J]. AJNR Am J Neuroradiol, 2008, 29(6):1176-1182. DOI:10.1007/s12149-012-0602-7.
[8] Li FM, Nie Q, Wang RM, et al. 11C-CHO PET in optimization of target volume delineation and treatment regimens in postoperative radiotherapy for brain gliomas[J]. Nucl Med Biol, 2012, 39(3):437-442. DOI:10.1016/j.nucmedbio.2011.10.003.
[9] Tan H, Chen L, Guan Y, et al. Comparison of MRI, F-18 FDG, and 11C-choline PET/CT for their potentials in differentiating brain tumor recurrence from brain tumor necrosis following radiotherapy[J]. Clin Nucl Med, 2011, 36(11):978-981. DOI:10.1097/RLU.0b013e31822f68a6.
[10] Li W, Ma L, Wang X, et al. 11C-choline PET/CT tumor recurrence detection and survival prediction in post-treatment patients with high-grade gliomas[J]. Tumour Biol, 2014, 35(12):12353-12360. DOI:10.1007/s13277-014-2549-x.
[11] Huang Z, Zuo C, Guan Y, et al. Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours[J]. Nucl Med Commun, 2008, 29(4):354-358. DOI:10.1097/MNM.0b013e3282f 4a21e.
[12] Takenaka S, Asano Y, Shinoda J, et al. Comparison of 11C-methionine, 11C-choline, and 18F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis[J]. Neurol Med Chir (Tokyo), 2014, 54(4):280-289. DOI:10.2176/nmc.oa2013-0117.
[13] Roelcke U, Bruehlmeier M, Hefti M, et al. F-18 choline PET does not detect increased metabolism in F-18 fluoroethyltyrosine-negative low-grade gliomas[J]. Clin Nucl Med, 2012, 37(1):e1-e3. DOI:10.1097/RLU.0b013e3182336100.
[14] Takenaka S, Asano Y, Shinoda J, et al. Comparison of 11C-methionine, 11C-choline, and 18F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis[J]. Neurol Med Chir (Tokyo), 2014, 54(4):280-289. DOI:10.2176/nmc.oa2013-0117.
[15] Ito K, Yokoyama J, Kubota K, et al. 18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy:the time period during which PET/CT can reliably detect non-recurrence[J]. Eur J Nucl Med Mol Imaging, 2010, 37(7):1318-1327. DOI:10.1007/s00259-010-1400-x.
[16] Ito K, Yokoyama J, Kubota K, et al. Comparison of 18F-FDG and 11C-choline PET/CT for detecting recurrences in patients with nonsquamous cell head and neck malignancies[J]. Nucl Med Commun, 2010, 31(11):931-937. DOI:10.1097/MNM.0b013e32833f3921.
[17] Wu HB, Wang QS, Wang MF, et al. Preliminary study of 11C-choline PET/CT for T staging of locally advanced nasopharyngeal carcinoma:comparison with 18F-FDG PET/CT[J]. J Nucl Med, 2011, 52(3):341-346. DOI:10.2967/jnumed.110.081190.
[18] Jiang J, Wu H, Huang M, et al. Variability of Gross Tumor Volume in Nasopharyngeal Carcinoma Using 11C-Choline and 18F-FDG PET/CT[J/OL]. PLoS One, 2015, 10(7):e0131801[2017-12-15]. https://www.ncbi.nlm.nih.gov/pubmed/26161910. DOI:10.1371/journal.pone. 0131801.
[19] 李昕, 王晴文, 姚树展, 等. 11C-胆碱PET/CT显像在肺癌中的应用价值及其机理的研究[J]. 医学影像学杂志, 2012, 22(4):546-551. DOI:10.3969/j.issn.1006-9011.2012.04.010. Li X, Wang QW, Yao SZ, et al. The research of 11C-choline PET/CT imaging and choline metabolism on lung cancer[J]. J Med Imaging, 2012, 22(4):546-551.
[20] Li M, Peng Z, Liu Q, et al. Value of 11C-choline PET/CT for lung cancer diagnosis and the relation between choline metabolism and proliferation of cancer cells[J]. Oncol Rep, 2013, 29(1):205-211. DOI:10.3892/or.2012.2099.
[21] 徐志英, 李善春, 谭贵萍, 等. 活动性结核18F-FDG联合11C-胆碱PET显像误诊肺癌一例[J]. 中华核医学与分子影像杂志, 2008, 28(6):417. DOI:10.3760/cma.j.issn.2095-2848.2008.06.022. Xu ZY, Li SC, Tan GP, et al. 18F-FDG combined with 11C-choline PET imaging of Active tuberculosis:misdiagnosed as lung cancer[J]. Chin J Nucl Med Mol Imaging, 2008, 28(6):417.
[22] Wu HB, Wang QS, Li BY, et al. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma[J]. Clin Nucl Med, 2011, 36(12):1092-1097. DOI:10.1097/RLU.0b013e3182335df4.
[23] Bieze M, Klümpen HJ, Verheij J, et al. Diagnostic accuracy of 18F-methylcholine positron emission tomography/computed tomography for intra- and extrahepatic hepatocellular carcinoma[J]. Hepatology, 2014, 59(3):996-1006. DOI:10.1002/hep.26781.
[24] Castilla-Lièvre MA, Franco D, Gervais P, et al. Diagnostic value of combining 11C-choline and 18F-FDG PET/CT in hepatocellular carcinoma[J]. Eur J Nucl Med Mol Imaging, 2016, 43(5):852-859. DOI:10.1007/s00259-015-3241-0.
[25] Lopci E, Torzilli G, Poretti D, et al. Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma[J]. Eur J Nucl Med Mol Imaging, 2015, 42(9):1399-1407. DOI:10.1007/s00259-015-3079-5.
[26] Kwee SA, Wong LL, Hernandez BY, et al. Chronic Liver Disease and the Detection of Hepatocellular Carcinoma by[18F]fluorocholine PET/CT[J]. Diagnostics(Basel), 2015, 5(2):189-199. DOI:10.3390/diagnostics5020189.
[27] Fartoux L, Balogova S, Nataf V, et al. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection[J]. Nucl Med Commun, 2012, 33(7):757-765. DOI:10.1097/MNM.0b013e328350fb9f.
[28] Nitsch S, Hakenberg OW, Heuschkel M, et al. Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT:Diagnosis and Initial Staging[J]. J Nucl Med, 2016, 57(Suppl 3):38S-42S. DOI:10.2967/jnumed.115.169748.
[29] Ceci F, Herrmann K, Castellucci P, et al. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer:results from a retrospective two-centre trial[J]. Eur J Nucl Med Mol Imaging, 2014, 41(12):2222-2231. DOI:10.1007/s00259-014-2872-x.
[30] Graziani T, Ceci F, Castellucci P, et al. 11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series[J]. Eur J Nucl Med Mol Imaging, 2016, 43(11):1971-1979. DOI:10.1007/s00259-016-3428-z.
[31] Eiber M, Rauscher I, Souvatzoglou M, et al. Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2017, 44(13):2179-2188. DOI:10.1007/s00259-017-3797-y.
[32] Jiménez LGA, García VAM, Amo-Salas M, et al. Role of 18F-Choline PET/CT in guiding biopsy in patients with risen PSA levels and previous negative biopsy for prostate cancer[J]. Rev Esp Med Nucl Imagen Mol, 2017, 36(4):241-246. DOI:10.1016/j.remn.2017. 01. 014.
[33] Garcia J R, Jorcano S, Soler M, et al. 11C-Choline PET/CT in the primary diagnosis of prostate cancer:impact on treatment planning[J]. Q J Nucl Med Mol Imaging, 2015, 59(3):342-350.
[34] López E, Lazo A, Gutiérrez A, et al. Influence of 11C-choline PET/CT on radiotherapy planning in prostate cancer[J]. Rep Pract Oncol Radiother, 2015, 20(2):104-112. DOI:10.1016/j.rpor.2014.11.008.
[35] Schwarzenböck SM, Kurth J, Ch G, et al. Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2013, 40(Suppl 1):S28-S35. DOI:10.1007/s00259-013-2404-0.
[36] Golan S, Sopov V, Baniel J, et al. Comparison of 11C-choline with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study[J]. J Urol, 2011, 186(2):436-441. DOI:10.1016/j.juro.2011.03.121.
[37] Brunocilla E, Ceci F, Schiavina R, et al. Diagnostic accuracy of 11C-choline PET/CT in preoperative lymph node staging of bladder cancer:a systematic comparison with contrast-enhanced CT and histologic findings[J]. Clin Nucl Med, 2014, 39(5):e308-e312. DOI:10.1097/RLU.00000000 00000342.
[38] Graziani T, Ceci F, Lopes FL, et al. 11C-choline PET/CT for restaging of bladder cancer[J]. Clin Nucl Med, 2015, 40(1):e1-e5. DOI:10.1097/RLU.0000000000000573.

相似文献/References:

[1]拓飞,张庆,张京,等.2014年度全国放射性核素γ能谱分析质量控制比对[J].国际放射医学核医学杂志,2015,39(5):401.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 011]
　tuo fei,zhang qing,zhang jing,et al.nationwide intercomparison for radionuclide analyses through γ-spectrometry method in 2014[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):401.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 011]
[2]李帅,李剑明.动脉粥样硬化易损斑块放射性核素标记分子探针的研究进展[J].国际放射医学核医学杂志,2015,39(1):80.[doi:10.3760/cma.j.issn.1673-4114.2015.01.017]
　Li Shuai,Li Jianming.Research progress of molecular probes labeled with radionuclide for imaging of atherosclerosis vulnerable plaque[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):80.[doi:10.3760/cma.j.issn.1673-4114.2015.01.017]
[3]段钰,李斌,高卉,等.神经内分泌肿瘤PET/CT的应用现状与进展[J].国际放射医学核医学杂志,2013,37(3):186.[doi:10.3760/cma.j.issn.1673-4114.2013.03.014]
　DUAN Yu,LI Bin,GAO Hui,et al.Application status and progress of PET/CT in neuroendocrine tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):186.[doi:10.3760/cma.j.issn.1673-4114.2013.03.014]
[4]展凤麟,汪世存,潘博,等.11C-胆碱和18F-FDG PET/CT显像在脑胶质瘤诊断中的应用[J].国际放射医学核医学杂志,2013,37(4):193.[doi:10.3760/cma.j.issn.1673-4114.2013.04.001]
　ZHAN Feng-lin,WANG Shi-cun,PAN Bo,et al.Application of 11C-choline and 18F-FDG PET/CT in diagnosing brain glioma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):193.[doi:10.3760/cma.j.issn.1673-4114.2013.04.001]
[5]彭武和,程静,曹庆东.核素肺通气/灌注显像在肺栓塞诊断中的现状及进展[J].国际放射医学核医学杂志,2012,36(2):80.[doi:10.3760/cma.j.issn.1673-4114.2012.02.005]
　PENG Wu-he,CHENG Jing,CAO Qing-dong.Present situation and development of the nuclide lung ventilation/perfusion imaging in diagnosis of lung embolim[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):80.[doi:10.3760/cma.j.issn.1673-4114.2012.02.005]
[6]陈红红,白光.《人体体表放射性核素污染处理规范》解读[J].国际放射医学核医学杂志,2012,36(4):200.[doi:10.3760/cma.j.issn.1673-4114.2012.04.001]
　CHEN Hong-hong,BAI Guang.Explanation of Specifwation of Decontamination for Radionuclides Contaminated Human Wound and Skin[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):200.[doi:10.3760/cma.j.issn.1673-4114.2012.04.001]
[7]刘庆芬,武权,樊体强,等.《放射性核素摄入量及内照射剂量估算规范》解读[J].国际放射医学核医学杂志,2012,36(4):214.[doi:10.3760/cma.j.issn.1673-4114.2012.04.005]
　LIU Qing-fen,WU Quan,FAN Ti-qiang,et al.Explanation of Specification for Assessments of Intakes and Internal Doses of Radionuclides[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):214.[doi:10.3760/cma.j.issn.1673-4114.2012.04.005]
[8]张富海,孟召伟,谭建.肺癌的放射性核素分子靶向治疗[J].国际放射医学核医学杂志,2012,36(3):145.[doi:10.3760/cma.j.issn.1673-4114.2012.03.005]
　ZHANG Fu-hai,MENG Zhao-wei,TAN Jian.Radionuclide molecular target therapy for lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):145.[doi:10.3760/cma.j.issn.1673-4114.2012.03.005]
[9]李亚军,张慧娟.放射性核素标记胆碱与18F-FDG PET肿瘤显像的对比研究[J].国际放射医学核医学杂志,2010,34(6):348.[doi:10.3760/cma.j.issn.1673-4114,2010.06.007]
　LI Ya-jun,ZHANG Hui-juan.Comparison choline with 18F-FDG PET in various tumors imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):348.[doi:10.3760/cma.j.issn.1673-4114,2010.06.007]
[10]姜磊.18F-氟脱氧葡萄糖和11C-胆碱在孤立性肺结节诊断中的应用[J].国际放射医学核医学杂志,2007,31(1):28.
　JIANG Lei.Diagnostic uses for 18F-fluorodeoxyglucose and 11C-choline in single pulmonary nodules[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):28.

备注/Memo

备注/Memo:
收稿日期:2017-12-16。
通讯作者:韩星敏,Email:xmhan@zzu.edu.cn
更新日期/Last Update: 2018-05-25